Amoxicillin and cephalexin are not interchangeable. Both are oral, bactericidal, beta-lactam antibiotics taken every 6 to 12 hours, but amoxicillin is an aminopenicillin that excels against Streptococcus, Enterococcus, and select gram-negative respiratory pathogens, while cephalexin is a first-generation cephalosporin built for skin and soft-tissue staph and strep coverage. The practical split: amoxicillin wins for ear infections, sinusitis, strep throat, and dental prophylaxis; cephalexin wins for cellulitis, wound infections, and uncomplicated urinary tract infections. Neither covers MRSA or atypical organisms, and true allergy cross-reactivity is far rarer than most patients are told.
Two beta-lactams, two different kill geometries
Both drugs bind penicillin-binding proteins (PBPs), the enzymes bacteria use to cross-link their peptidoglycan cell wall. Blocking those enzymes stops wall construction, the bacterium bursts under osmotic pressure, and the infection clears. The difference is which PBPs each molecule grabs and how well it survives bacterial defenses.
Amoxicillin, an aminopenicillin, adds an amino side chain to the penicillin core. That side chain widens its grip on PBP1 and PBP3 in gram-negative bacteria, which is why amoxicillin reaches Haemophilus influenzae and Moraxella catarrhalis when paired with clavulanate. It also keeps excellent activity against Enterococcus faecalis, a bug cephalexin essentially ignores.
Cephalexin, a first-generation cephalosporin, carries a six-membered dihydrothiazine ring instead of penicillin's five-membered thiazolidine ring. That geometry resists many penicillinases produced by Staphylococcus aureus, so cephalexin holds up against staph strains that would chew through plain amoxicillin. The trade-off: it loses gram-negative reach and has no meaningful Enterococcus activity.
In plain terms: amoxicillin is tuned for respiratory and oral flora, cephalexin for skin and urinary flora. Neither is stronger. They point in different directions.
Absorption kinetics separate them further. Amoxicillin peaks in serum at roughly 1.5 to 2 hours and reaches about 60 to 80 percent oral bioavailability. Cephalexin absorbs almost completely, near 90 percent, and peaks around 1 hour. Both clear through the kidneys largely unchanged, so renal dosing matters for both.
Quantified head-to-head: spectrum, dosing, and cost
The table below reconciles the practical differences. Every threshold in this article is expressed in US customary units and milligram (mg) doses, consistent with US labeling.
| Feature | Amoxicillin | Cephalexin |
|---|---|---|
| Drug class | Aminopenicillin | First-generation cephalosporin |
| Standard adult dose | 500 mg every 8 hours, or 875 mg every 12 hours | 250–500 mg every 6 hours, up to 1 g every 6 hours for severe infection |
| Typical duration, uncomplicated | 5–10 days (strep pharyngitis often 10 days) | 5–7 days for cellulitis; 5–7 days for uncomplicated cystitis |
| Best gram-positive targets | Streptococcus pyogenes, Streptococcus pneumoniae, Enterococcus faecalis | Staphylococcus aureus (methicillin-susceptible), S. pyogenes |
| Best gram-negative targets | H. influenzae, M. catarrhalis (with clavulanate), E. coli (variable) | E. coli, Klebsiella pneumoniae, Proteus mirabilis |
| MRSA activity | None | None |
| Atypical coverage (Mycoplasma, Chlamydia) | None | None |
| Food effect | Minimal | Minimal |
| Renal adjustment threshold | Reduce dose below creatinine clearance of 30 mL/min | Reduce dose below creatinine clearance of 15 mL/min |
| Typical US cash price, 10-day course | USD 5–15 | USD 10–25 |
The dose difference is not cosmetic. Amoxicillin's higher per-dose milligram strength reflects its lower potency against gram-negatives and its need to sustain free drug above the minimum inhibitory concentration (MIC) for a larger fraction of the dosing interval. Cephalexin relies on a shorter interval, every 6 hours, to keep levels above the MIC because it clears faster.
When amoxicillin is the right call
Amoxicillin is the first-line oral agent for acute otitis media in children who have not taken amoxicillin in the prior 30 days, per the 2013 American Academy of Pediatrics guideline. The standard high-dose pediatric regimen is 80 to 90 mg per kilogram per day, split into two doses, because it overcomes intermediate penicillin resistance in S. pneumoniae.
Strep pharyngitis is amoxicillin's second stronghold. A single daily dose of 50 mg per kilogram (maximum 1 g) for 10 days eradicates Group A Streptococcus in roughly 85 to 90 percent of cases. Cephalexin also works here, and it is the usual fallback when a nonspecific penicillin rash occurs, but amoxicillin remains the cheaper, narrower-spectrum default.
Acute bacterial rhinosinusitis, dental abscess prophylaxis, and endocarditis prophylaxis before dental work all sit firmly in amoxicillin territory. For endocarditis prophylaxis in patients with the highest-risk cardiac conditions, the standard adult dose is 2 g taken 30 to 60 minutes before the procedure, per the 2021 American Heart Association guidance.
The non-obvious detail: amoxicillin's value in respiratory infection depends on the clavulanate partner, not amoxicillin alone. Amoxicillin-clavulanate extends coverage to beta-lactamase-producing H. influenzae, which accounts for 20 to 40 percent of H. influenzae isolates in some US regions.
When cephalexin is the right call
Cephalexin is a first-line oral option for nonpurulent cellulitis, the red, warm, spreading skin infection without a drainable pus collection. The dominant pathogen there is beta-hemolytic Streptococcus, with S. aureus as a secondary player, and cephalexin hits both. A typical regimen is 500 mg every 6 hours for 5 to 7 days, extended to 7 to 14 days if the cellulitis is extensive or slow to improve.
For uncomplicated cystitis in patients who cannot take first-line nitrofurantoin or trimethoprim-sulfamethoxazole, cephalexin at 500 mg every 12 hours for 5 to 7 days is a reasonable alternative, per the 2010 Infectious Diseases Society of America uncomplicated cystitis guideline. It is not the preferred first choice, but it works against the common E. coli and Klebsiella isolates.
Cephalexin also serves as the go-to alternative for patients with a documented penicillin allergy who need a strep or staph cover. This is where the most important misconception lives.
The penicillin-allergy misconception
Most people labeled penicillin-allergic are not. Roughly 90 percent of patients reporting a penicillin allergy can tolerate the drug when formally tested, and about 80 percent of those labels fade within 10 years because specific IgE antibodies wane. The label itself is harmful: it pushes patients toward broader-spectrum antibiotics, increases C. difficile infection risk, and lengthens hospital stays.
The cross-reactivity between penicillins and first-generation cephalosporins is much lower than old teaching suggested. Shared beta-lactam rings matter, but the immunologically important side chains differ. For first-generation cephalosporins like cephalexin, the estimated cross-reactivity rate with penicillins is around 1 to 2 percent, and many of those reactions are mild rashes rather than anaphylaxis. A patient with a remote, non-severe rash after amoxicillin is usually a candidate for cephalexin and, in many cases, for direct amoxicillin challenge under supervision.
A second misconception: amoxicillin does not cover MRSA, and neither does cephalexin. If an infection has a drainable abscess, the treatment is incision and drainage, not a pill. Adding cephalexin to drainage does not reliably improve outcomes for uncomplicated abscesses in the era of MRSA.
Rash, allergy, or something else: a practical timeline
Timing tells you a lot about what a reaction means. The table below maps common reaction patterns to likely mechanisms.
| Timing after first dose | Pattern | Likely cause |
|---|---|---|
| Within 1 hour | Hives, wheeze, swelling, low blood pressure | Immediate IgE-mediated allergy; stop drug, seek emergency care |
| 24–72 hours | Flat pink rash, no itch, no fever | Non-allergic amoxicillin rash, common with viral illness like Epstein-Barr |
| 3–10 days | Itchy raised rash | Delayed maculopapular drug eruption; often managed with antihistamines after clinician review |
| 5–14 days | Rash plus fever, facial swelling, lymph node swelling | Drug reaction with eosinophilia and systemic symptoms (DRESS); urgent evaluation |
| 1–6 weeks | Severe blistering, skin peeling | Stevens-Johnson syndrome or toxic epidermal necrolysis; emergency |
| Any time after prior course | Recurrent rash on re-exposure | Possible sensitization; allergy evaluation before reuse |
Seek emergency care immediately for any of the following:
- Swelling of the lips, tongue, or throat, or difficulty breathing
- Hives spreading across the body with dizziness or faintness
- Blistering or peeling skin, especially inside the mouth or eyes
- Rash with high fever, facial swelling, or swollen lymph nodes
- Bloody or severe watery diarrhea during or up to 8 weeks after the course
- New joint pain or dark urine after starting either drug
The bloody diarrhea warning matters because both drugs can trigger Clostridioides difficile infection, which appears in roughly 1 to 3 percent of outpatient antibiotic courses depending on the agent and patient risk. Amoxicillin-clavulanate carries a higher C. difficile risk than cephalexin in most surveillance data.
What actually to do when facing the choice
Step one is naming the infection, not the drug. The pathogen and site decide the antibiotic; patient preference and price come later. The following actions keep the decision clean.
- Identify the infection site and likely organism with your clinician before filling any prescription; a sore throat needs a rapid strep test before antibiotics, and a skin infection needs a trained eye to distinguish cellulitis from a contact rash.
- If you carry a penicillin-allergy label, ask whether it can be evaluated or removed rather than worked around; direct oral challenge is increasingly used for low-risk histories.
- Take the full prescribed course even if you feel better in 48 hours, because incomplete courses drive resistance and relapse.
- Space doses evenly, every 6 hours for cephalexin and every 8 or 12 hours for amoxicillin, and set phone alarms; missed doses are the most common reason for treatment failure.
- Report any rash with its exact timing and appearance, because the timing changes the diagnosis and the next prescription.
- Do not share leftover antibiotics or self-treat with either drug; neither covers viral colds, flu, or most bronchitis.
Get medical advice before starting either drug if you are pregnant, breastfeeding, have kidney disease, or take warfarin. Cephalexin can raise the international normalized ratio (INR) modestly, and amoxicillin can do the same unpredictably.
Limits of the evidence and where it stays uncertain
Direct head-to-head randomized trials of amoxicillin versus cephalexin are scarce. Most comparative conclusions rest on spectrum data, pharmacokinetic modeling, and observational cohorts rather than large parallel trials. For strep pharyngitis, both drugs show bacteriological cure rates above 85 percent, but the comparative advantage of one over the other in symptom duration is small and inconsistently measured.
The optimal duration for cellulitis remains debated, with trials supporting 5 days in uncomplicated cases and others suggesting 6 to 7 days reduces relapse in patients with comorbidities. Cephalexin dosing frequency (every 6 hours versus every 8 to 12 hours) lacks strong comparative data despite decades of use.
Cross-reactivity estimates between penicillins and cephalosporins vary by study design and by which cephalosporin generation is examined; the 1 to 2 percent figure applies best to first-generation agents and should not be generalized to all cephalosporins. Amoxicillin's Enterococcus coverage is well established, but whether that coverage translates into better outcomes in polymicrobial infections is inferred rather than proven.
Finally, local resistance patterns shift. E. coli resistance to amoxicillin exceeds 40 to 50 percent in many US regions, which is why amoxicillin is not a cystitis drug. Cephalexin's staph coverage assumes methicillin-susceptible S. aureus; in communities where MRSA accounts for more than 50 percent of staph skin infections, cephalexin may fail, and culture guidance becomes essential. These numbers are moving targets, and clinicians should check local antibiograms rather than rely on national averages.